Lyne Labs cited for inadequate lab controls
This article was originally published in The Gold Sheet
Lyne Laboratories of Brockton, Mass., was cited for inadequate lab controls in a Jan. 17 warning letter. The firm, a contract manufacturer of oral liquids, powders, semi-solids, tablets and liquid dose unit-dose packaging, was cited for failing to thoroughly review the failure of a batch or any of its components to meet specifications. FDA said the company has not completed an investigation into the chemical composition and potential patient risk for particulate matter found in its Calcitriol Injection. The firm was also cited for failure to establish adequate laboratory controls including scientifically sound and appropriate test procedures to assure that drug product components and drug products conform to appropriate standards of identity, strength, quality and purity
You may also be interested in...
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.